152 related articles for article (PubMed ID: 21590688)
41. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.
Krishnan Y; Al Awadi S; Sreedharan PS; Sujith Nair S; Thuruthel S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e30-7. PubMed ID: 23937427
[TBL] [Abstract][Full Text] [Related]
42. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
[TBL] [Abstract][Full Text] [Related]
43. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
44. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
45. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
46. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
47. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
48. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
[TBL] [Abstract][Full Text] [Related]
50. Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients.
Kanazawa T; Akashi-Tanaka S; Iwamoto E; Takasugi M; Shien T; Kinoshita T; Miyakawa K; Shimizu C; Ando M; Katsumata N; Fujiwara Y; Fukutomi T
Breast J; 2005; 11(5):311-6. PubMed ID: 16174150
[TBL] [Abstract][Full Text] [Related]
51. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
52. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Hanusch C; Schneeweiss A; Loibl S; Untch M; Paepke S; Kümmel S; Jackisch C; Huober J; Hilfrich J; Gerber B; Eidtmann H; Denkert C; Costa S; Blohmer JU; Engels K; Burchardi N; von Minckwitz G
Clin Cancer Res; 2015 Jul; 21(13):2924-31. PubMed ID: 25825476
[TBL] [Abstract][Full Text] [Related]
53. Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.
Zer A; Rizel S; Braunstein R; Yerushalmi R; Hendler D; Neimann V; Cioreuru N; Sulkes A; Stemmer SM
Chemotherapy; 2012; 58(2):95-101. PubMed ID: 22377846
[TBL] [Abstract][Full Text] [Related]
54. LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.
Rusz O; Papp O; Vízkeleti L; Molnár BÁ; Bende KC; Lotz G; Ács B; Kahán Z; Székely T; Báthori Á; Szundi C; Kulka J; Szállási Z; Tőkés AM
Cancer Chemother Pharmacol; 2018 Jul; 82(1):139-147. PubMed ID: 29770955
[TBL] [Abstract][Full Text] [Related]
55. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant chemotherapy of breast cancer.
Garces CA; Cance WG
Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
Lin Y; Wang C; Huang X; Zhou X; Zhou Y; Mao F; Guan J; Song Y; Zhong Y; Xu Y; Sun Q
Breast Cancer Res Treat; 2019 Jun; 175(3):659-666. PubMed ID: 30937656
[TBL] [Abstract][Full Text] [Related]
58. CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Zhou X
Clin Breast Cancer; 2014 Apr; 14(2):e33-40. PubMed ID: 24393851
[TBL] [Abstract][Full Text] [Related]
59. Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?
Alkan A; Sahin U; Altundag K
Med Oncol; 2010 Dec; 27(4):1430. PubMed ID: 19876779
[No Abstract] [Full Text] [Related]
60. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
Caudle AS; Gonzalez-Angulo AM; Hunt KK; Liu P; Pusztai L; Symmans WF; Kuerer HM; Mittendorf EA; Hortobagyi GN; Meric-Bernstam F
J Clin Oncol; 2010 Apr; 28(11):1821-8. PubMed ID: 20231683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]